SPRY
ARS Pharmaceuticals Inc

2,449
Mkt Cap
$832.11M
Volume
2.22M
52W High
$18.90
52W Low
$6.66
PE Ratio
-4.82
SPRY Fundamentals
Price
$8.24
Prev Close
$8.38
Open
$8.23
50D MA
$10.10
Beta
1.25
Avg. Volume
1.01M
EPS (Annual)
-$1.74
P/B
7.28
Rev/Employee
$533,405.06
$1,000.28
Loading...
Loading...
News
all
press releases
ARS Pharmaceuticals Q4 Earnings Call Highlights
ARS Pharmaceuticals (NASDAQ:SPRY) executives used the company's fourth-quarter and full-year 2025 earnings call to outline early commercial progress for neffy, its needle-free epinephrine option for...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
ARS Pharmaceuticals: Q4 Earnings Insights
read more...
Benzinga·4d ago
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -0.96% and +9.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Exploring ARS Pharmaceuticals's Earnings Expectations
read more...
Benzinga·7d ago
News Placeholder
ARS Pharmaceuticals (SPRY) Expected to Announce Earnings on Monday
ARS Pharmaceuticals (NASDAQ:SPRY) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...
MarketBeat·9d ago
News Placeholder
Canadian Natural to Report Q4 Earnings: What's in the Offing?
CNQ gears up to report Q4 earnings as lower price realizations and soft gas weigh on estimates despite record output and strong cash flow.
Zacks·10d ago
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·11d ago
News Placeholder
ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Zacks Research
Zacks Research upgraded ARS Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Wednesday...
MarketBeat·14d ago
News Placeholder
Levin Capital Strategies L.P. Increases Holdings in ARS Pharmaceuticals, Inc. $SPRY
Levin Capital Strategies L.P. boosted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 157.6% in the 3rd quarter, according to the company in its most recent disclosure...
MarketBeat·22d ago
News Placeholder
CenterBook Partners LP Invests $5.15 Million in ARS Pharmaceuticals, Inc. $SPRY
CenterBook Partners LP acquired a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·22d ago
<
1
2
...
>

Latest SPRY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.